Understand the source comparison
Follistatin-344 Research Review: Isoform Comparison and Application Contexts
The following table clarifies when to select follistatin-344 versus alternative isoforms or myostatin inhibitors in research design. Tissue Localization High (heparin-binding domain) Low (circulates systemically) Moderate (co-secreted with myostatin) Low (syst
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table clarifies when to select follistatin-344 versus alternative isoforms or myostatin inhibitors in research design.
- Tissue Localization
- High (heparin-binding domain)
- Low (circulates systemically)
- Moderate (co-secreted with myostatin)
- Low (systemic antibody construct)
- Use FS-344 for localized muscle studies; FS-315 for systemic endocrine research
- Myostatin Binding Affinity
- Kd ≈ 300 pM
- Kd ≈ 5 nM
- Kd ≈ 1 nM
- FS isoforms have 10–15× tighter binding than propeptide or decoy receptors
- Off-Target Effects
- Binds activin A/B, GDF-11, BMP-7
- Myostatin-specific
- Broad ActRIIB ligand blockade
- Myostatin propeptide offers highest selectivity; follistatins affect multiple pathways
- Plasma Half-Life
- 3–4 hours
- 2–3 hours
- 10–14 days
- ActRIIB-Fc decoy requires weekly dosing; follistatins and propeptide need daily administration
- Tissue Retention Duration
- 24–48 hours (proteoglycan binding)
- <6 hours (rapid renal clearance)
- 12–18 hours
- Not applicable
- FS-344 sustains local activity longer than plasma T½ suggests
- Evidence Base
- Moderate (gene therapy > peptide)
- Limited (mostly pharmacokinetic)
- Moderate (preclinical hypertrophy models)
- Strong (completed Phase II trials in sarcopenia)
- ActRIIB-Fc has the most advanced clinical data; follistatin-344 gene therapy is validated but peptide form is less studied
- Follistatin-344 is the correct tool when your research question involves localized muscle hypertrophy, satellite cell activation, or tissue-specific myostatin inhibition. If you're modeling systemic metabolic effects. Hepatic glucose handling, reproductive axis modulation, erythropoiesis. Follistatin-315 or an ActRIIB decoy receptor provides more relevant systemic distribution. For myostatin-selective experiments with minimal off-target confounding, myostatin propeptide is the cleaner reagent.